Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Mete-analysis of adjuvant immunochemotherapy using OK-432 in patients withresected non-small-cell lung cancer
Autore:
Sakamoto, J; Teramukai, T; Watanabe, Y; Hayata, Y; Okayasu, T; Nakazato, N; Ohashi, Y;
Indirizzi:
Aichi Prefectural Hosp, Dept Surg, Aichi 4440011, Japan Aichi Prefectural Hosp Aichi Japan 4440011 pt Surg, Aichi 4440011, Japan Aichi Prefectural Hosp, Lab Clin Oncol, Aichi 4440011, Japan Aichi Prefectural Hosp Aichi Japan 4440011 n Oncol, Aichi 4440011, Japan Amgen Ltd, Therapeut Prod Dev, Tokyo, Japan Amgen Ltd Tokyo JapanAmgen Ltd, Therapeut Prod Dev, Tokyo, Japan Kanazawa Univ, Dept Surg 1, Kanazawa, Ishikawa 920, Japan Kanazawa Univ Kanazawa Ishikawa Japan 920 , Kanazawa, Ishikawa 920, Japan Tokyo Med Univ, Dept Surg, Tokyo, Japan Tokyo Med Univ Tokyo JapanTokyo Med Univ, Dept Surg, Tokyo, Japan Hokkaido Univ, Dept Surg 2, Sapporo, Hokkaido, Japan Hokkaido Univ Sapporo Hokkaido Japan pt Surg 2, Sapporo, Hokkaido, Japan Yokoyama Gastrointestinal Hosp, Dept Surg, Tokyo, Japan Yokoyama Gastrointestinal Hosp Tokyo Japan osp, Dept Surg, Tokyo, Japan Univ Tokyo, Sch Hlth Sci & Nursing, Dept Biostat, Tokyo, Japan Univ TokyoTokyo Japan h Hlth Sci & Nursing, Dept Biostat, Tokyo, Japan
Titolo Testata:
JOURNAL OF IMMUNOTHERAPY
fascicolo: 3, volume: 24, anno: 2001,
pagine: 250 - 256
SICI:
1524-9557(200105/06)24:3<250:MOAIUO>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
STREPTOCOCCAL PREPARATION OK-432; HUMAN-TUMOR-CELLS; CURATIVE RESECTION; COLORECTAL-CANCER; PICIBANIL OK-432; PLEURAL EFFUSION; GASTRIC-CANCER; CLINICAL-VALUE; BREAST-CANCER; IMMUNOTHERAPY;
Keywords:
OK-432; non-small-cell lung cancer; meta-analysis; adjuvant immunochemotherapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
50
Recensione:
Indirizzi per estratti:
Indirizzo: Sakamoto, J Aichi Prefectural Hosp, Dept Surg, 18 Kuriyado, Aichi 4440011,Japan Aichi Prefectural Hosp 18 Kuriyado Aichi Japan 4440011 Japan
Citazione:
J. Sakamoto et al., "Mete-analysis of adjuvant immunochemotherapy using OK-432 in patients withresected non-small-cell lung cancer", J IMMUNOTH, 24(3), 2001, pp. 250-256

Abstract

The benefits of immunochemotherapy with a penicillin-treated lyophilized preparation of Streptococcus pyogenes, OK-432 (Picibanil), were reassessed in patients with resected non-small-cell lung cancer through a meta-analysisbased on data from 1,520 patients enrolled in 11 randomized clinical trials. All 11 trials were started before 1991, and the subjects had been followed up for ae lease 5 years after surgery and randomization. In these trials, standard chemotherapy was compared with the same therapy plus OK-432. Theendpoint of interest was overall survival, and analysis was based on intent-to-treat population without patient exclusion. Data were analyzed using the Mantel-Haenszel method. The 5-year survival rate for all eligible patients in the 11 trials was 51.2% in the immunochemotherapy group versus 43.7% in the chemotherapy group. The odds ratio (OR) for overall survival was 0.70 (95% CI = 0.56-0.87, p = 0.0010). Analysis of four trials in which central randomization was performed also reconfirmed a significantly longer survival time for the immunochemotherapy group (OR = 0.66, 95% CI = 0.44-1.00, p= 0.049). Based on these results of meta-analysis, it is postulated that postoperative adjuvant immunochemotherapy using OK-432 might improve the survival of patients after resection of non-small-cell lung cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 10:40:54